# Resilience Care account plan

> Resilience Care is a French remote patient monitoring company in oncology, psychiatry and gastroenterology, used by over 42,000 patients in 220+ facilities.

## At a glance

Resilience Care, founded in 2021 by Céline Lazorthes and Jonathan Benhamou and co-founded with Gustave Roussy, sells remote patient monitoring: a patient app plus a Class IIa medical device platform for healthcare professionals. In October 2023 it became the first remote monitoring medical device in oncology reimbursed by French social security; hospitals and cancer centers prescribe it and patients are reimbursed. By September 2026 it covered oncology, psychiatry and gastroenterology, used in routine care by over 42,000 patients across more than 220 healthcare facilities in France, Belgium and Germany, and entered the United States in March 2026. It is venture-backed (a €40M Series A in 2022 and $25M in May 2024 led by Picus Capital and Red River West) and had 150 employees in May 2024; no revenue is disclosed.

## Business units

- **Oncology remote monitoring**: The original product: symptom tracking, therapeutic education and supportive care for cancer patients, reimbursed in France and pitched in the U.S. to oncology providers on nurse efficiency and early toxicity detection. The U.S. business is led by Greg Orr, General Manager, U.S.
- **Psychiatry remote monitoring**: Monitoring for mood disorders (depression and bipolar disorders), implemented in over 25 healthcare facilities in France with partners including Ramsay Santé and Inicea. The September 2026 acquisition of Recovery Cat adds nearly 20 German hospitals and practices and a care contract with Techniker Krankenkasse.
- **Gastroenterology**: Added in November 2023 through the acquisition of GutyCare, a French platform for following patients in gastroenterology and immunology.
- **Clinical research and pharma services**: An RPM platform launched in September 2023 helps pharma companies monitor patients in clinical trials, and real-world data from the medical device feeds a Health Data Warehouse used in over 20 academic and industry-sponsored clinical studies.

## Strategic priorities

- **European expansion, with Germany first**: Resilience Care acquired Germany-based Recovery Cat on 24 September 2026 to "accelerate its footprint in Germany"; Recovery Cat's centers will gradually transition to Resilience Care's platform.
- **U.S. market entry in oncology**: Formal U.S. expansion was announced from Boston on 31 March 2026, with a U.S. leadership team hired from digital health and pharma.
- **Multi-pathology remote monitoring**: The long-term goal is "to become the European leader in remote follow-up care for patients with chronic diseases", reusing one medical and sales organisation across conditions.
- **Reimbursement in each country**: After French reimbursement in October 2023, Resilience filed with the Belgian agency INAMI in January 2024 and negotiated with BfArM in Germany; in Germany it now has a selective care contract with Germany's largest statutory health insurer.
- **Clinical evidence and pharma trials**: The company runs clinical studies and wants to accelerate clinical trials and collaborations with laboratories.

## Investments and deals

- **Recovery Cat acquisition**: Announced 24 September 2026: a Charité spin-out co-founded in 2020 by Dr. Jakob Kaminski, with a therapy-monitoring platform for severe psychiatric disorders; no price was disclosed.
- **GutyCare acquisition**: November 2023 purchase of a French gastroenterology and IBS monitoring platform.
- **$25M funding round**: Raised in May 2024, led by Picus Capital and Red River West with Cathay Innovation, Singular and Seaya Ventures, after a €40M Series A in January 2022.
- **U.S. team**: The March 2026 U.S. launch added Greg Orr as General Manager, Eddie Martucci as President, U.S., and industry and nursing advisors.

## Challenges and risks

- **Fragmented reimbursement**: Benhamou notes each European country has its specificities; reimbursement must be won country by country, as in Belgium and Germany.
- **Integrating an acquisition abroad**: Recovery Cat's centers must migrate to Resilience Care's platform while keeping their German partnerships and insurer contract.
- **Proving value in a new U.S. market**: In the U.S. the pitch rests on nurse efficiency and new revenue streams for practices rather than on national reimbursement as in France.
- **Short-staffed hospital customers**: Hospitals are often short-staffed, which is both the problem the product addresses and a constraint on deploying it.

## What leadership says

> "By integrating Recovery Cat, a company with a strong partners network, solid scientific foundations, deep local expertise, and a care contract with Germany's largest insurer, we are strengthening our position as a European player and advancing our ambition to make remote monitoring a standard of care." — Jonathan Benhamou, co-founder & CEO, Recovery Cat acquisition release, 24 September 2026

> "We are helping care teams see risk before it becomes an emergency." — Greg Orr, General Manager, U.S., U.S. expansion release, 31 March 2026

> "Our goal is to integrate these capabilities into routine care in the US to support both patients and clinicians." — Charles Ferté, Chief Medical and Patient Experience Officer, U.S. expansion release, 31 March 2026

> "This financing will allow us to extend the positive impacts of remote monitoring, therapeutic education, and supportive care to a greater number of patients in France and abroad." — Céline Lazorthes and Jonathan Benhamou, co-founders and co-CEOs, $25M funding press release, 21 May 2024


## Where a supplier can help

- **Platform integration and migration**: Tied to the Recovery Cat integration: data migration, interoperability and hospital IT integration services help move German centers onto Resilience Care's platform.
- **U.S. go-to-market**: Tied to the U.S. market entry: prospecting, sales enablement and market access support fit a new team selling to oncology providers.
- **Market access and reimbursement**: Tied to the fragmented reimbursement challenge: health economics, regulatory and payer-contracting expertise supports country-by-country approvals.
- **Clinical trial operations**: Tied to the pharma trials priority: CRO partnerships and real-world data tooling support the clinical trials RPM platform.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Resilience raises $25 million to accelerate the deployment of patient remote monitoring in France and internationally (press release)](https://www.cathaycapital.com/resilience-raises-25-million-to-accelerate-the-deployment-of-patient-remote-monitoring-in-france-and-internationally/)

Report · 2024-05-21

- Resilience sells a remote patient care solution for cancer patients: a mobile app for patients plus a Remote Patient Monitoring (RPM) platform for care teams, which is a Class IIa medical device. It was co-founded with Gustave Roussy.
- Scale at the round: deployed in more than 90 medical centers and supporting over 10,000 patients.
- In October 2023 it became the first remote-monitoring medical device in oncology to be reimbursed by French national social security, after the HAS validated its clinical and organisational impact.
- Funding: a first €5M in March 2021, a €40M Series A in January 2022, then this $25M round. Picus Capital and Red River West led it, and Cathay Innovation, Singular and Seaya Ventures followed on.
- International plan: Belgium first, where three centers already use it (Jules Bordet Institute, CHU Saint Pierre, Clinique Saint-Luc Bouge) and an INAMI reimbursement application was filed in January 2024. Germany comes next, with 500,000 new cancers a year.
- Research: 19 ongoing clinical studies and two European projects (CARE1, coordinated by Gustave Roussy, and e-Quol). Real-world data sits in its own data warehouse.
- Ambition: to become the European leader in remote follow-up care for patients with chronic diseases.

### [Remote Patient Monitoring in Psychiatry: Resilience Care Acquires Recovery Cat to Accelerate European Expansion](https://www.resilience.care/resilience-resources/resilience-care-acquires-recovery-cat)

Report · 2026-09-24

- Resilience Care has bought Recovery Cat, a Berlin spin-off of Charité – Universitätsmedizin Berlin that runs a therapy-monitoring platform for people with severe psychiatric disorders.
- Recovery Cat is deployed in nearly 20 hospitals and practices. It holds a selective care contract with Techniker Krankenkasse (TK), Germany's largest statutory health insurer: patients get the app free and providers are reimbursed for therapy monitoring.
- Resilience Care's scale: more than 220 healthcare facilities across France, Belgium and Germany, over 42,000 patients in routine care, and over 20 clinical studies.
- It now covers three specialties: oncology, psychiatry and gastroenterology. Its psychiatry RPM for mood disorders (depression, bipolar disorders) runs in more than 25 French facilities, with Ramsay Santé and Inicea (Clariane Group) among its partners.
- Recovery Cat's centers will move onto Resilience Care's platform over the coming months.
- Jonathan Benhamou, named "co-founder & CEO", frames the deal as a step to "strengthening our position as a European player" and making remote monitoring a standard of care.

### [Resilience Care Expands to U.S. Market, Adds Veteran Digital Health Leaders to Support Growth with Oncology Providers](https://www.resilience.care/resilience-resources/resilience-care-expands-us-market)

Report · 2026-03-31

- On 31 March 2026, in Boston, Resilience Care announced its formal expansion into the United States with its digital oncology platform, aimed at the "between-visit blind spot" in cancer care.
- Scale claimed: implemented in over 200 clinical centers and supporting more than 35,000 patients in Europe.
- US team: Greg Orr is General Manager, U.S.; he was COO and CCO of Jasper Health, with partnerships including Memorial Sloan Kettering, Evernorth and UnitedHealthcare. Eddie Martucci, PhD, co-founder of Akili Interactive, is President, U.S.
- Advisors: Jill DeSimone, former President of U.S. Oncology at Merck, and Anne Ireland, DNP, formerly of City of Hope. Dr. Ethan Basch has advised the company almost since its inception.
- Claimed outcomes: a 4-5x increase in nursing capacity, 85% patient adherence after a full year, and 92% clinician satisfaction. Cited research shows up to 38% fewer hospitalizations, 25% fewer severe treatment-related toxicities, and treatment extended by 1.9 months on average.
- US pitch: help practices "detect treatment toxicities early", maximise nurse efficiency, and "capture new revenue streams through proactive, data-driven care".

### [Resilience lève 25 millions de dollars pour déployer sa télésurveillance médicale à l'international (Maddyness)](https://www.maddyness.com/2024/05/21/resilience-leve-25-millions-de-dollars-pour-deployer-sa-telesurveillance-medicale-a-linternational/)

Executive talk · Jonathan Benhamou, Co-founder and Co-CEO · 2024-05-21

- Jonathan Benhamou explains the product: a tool to "better understand the mechanisms of drug toxicity" (translated). It lets care teams adjust treatment to side effects and schedule appointments when needed (translated).
- Business model: "Like a drug, a professional can prescribe our solution and the patient is reimbursed by social security" (translated). Resilience works with 90 partner hospitals.
- A second line of business with pharma: clinical trials, research consortia, and work on childhood cancers.
- Diversification: the GutyCare platform (gastroenterology and immunology, including chronic inflammatory bowel disease) was acquired six months before this article. The idea is to reuse the same doctors and sales teams for other conditions.
- International: reimbursement steps under way in Belgium and Germany targeted. "Today we are mainly looking at our European neighbours. Then we will study the USA" (translated).
- 150 employees, with 50 to 100 hires planned over the next 18 months. The $25M came from Picus Capital, Red River West and historical investors.

### [Innovating for Life: supporting Resilience's Mission in Remote Care (Red River West investor letter)](https://redriverwest.substack.com/p/innovating-for-life-supporting-resiliences)

Report · 2024-05-27

- Red River West, co-lead of the $25M round with Picus Capital, explains why it invested in Resilience, a remote patient monitoring (RPM) platform for cancer care.
- Product: a patient mobile app plus an RPM platform. It covers symptom tracking through questionnaires shared with the care team, with alerts, and digital support programs (physical activity, meditation, yoga, Cognitive Behavioral Therapy), enhanced by machine learning.
- Traction: over 90 medical centers and more than 10,000 patients. First oncology RPM device reimbursed by French social security, in October 2023.
- Second business line: in September 2023 Resilience launched an RPM platform for pharma companies to monitor patients in clinical trials, and it already has "several pharmaceutical customers". The investor sees this as the mid-term US opportunity (the CRO market was estimated at $60B in 2023).
- New condition: in November 2023 Resilience acquired GutyCare, a French IBS monitoring platform.
- Expansion: Belgium and Germany first. In Germany Resilience is negotiating with the regulator BfArM to bring RPM apps into reimbursement (the DiGA framework). The investor expects a European lead before targeting the US.

## Questions about Resilience Care

### What does Resilience Care do?

It provides remote patient monitoring, a patient app linked to a medical device platform for clinicians, in oncology, psychiatry and gastroenterology, plus monitoring for pharma clinical trials.

### Where does Resilience Care operate?

In France, Belgium and Germany, across more than 220 healthcare facilities, and in the United States since its March 2026 oncology launch.

### How many employees does Resilience Care have?

The company had 150 employees in May 2024 and planned to recruit 50 to 100 people over the following 18 months.

### Who leads Resilience Care?

Co-founders Jonathan Benhamou and Céline Lazorthes; the September 2026 release names Jonathan Benhamou as co-founder & CEO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
